ABT
Abbott Laboratories
$95.84
+0.21 (+0.22%)
At close · Jul 7
Market Cap
$166.94B
Shares
1,741,812,429
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$44.33B
+5.7%
FY2025
Net Income
$6.52B
-51.3%
FY2025
Gross Margin
56.42%
+1pp
FY2025
Operating Margin
18.17%
+1.9pp
FY2025
Diluted EPS
$3.72
-51.3%
FY2025
Operating Cash Flow
$9.57B
+11.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $45.13B | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B | $34.61B | $31.9B | $30.58B | $27.39B | $20.85B | $20.41B | $20.25B | $19.66B | $19.05B | $21.41B | $35.17B | $30.76B | $29.53B | $25.91B | |
| $19.74B | $19.32B | $18.71B | $17.98B | $19.14B | $18.54B | $15B | $13.23B | $12.71B | $12.41B | $9.09B | $8.75B | $9.22B | $9.19B | $8.9B | $10.02B | $14.67B | $13.21B | $12.61B | $11.42B | |
| $25.39B | $25.01B | $23.24B | $22.13B | $24.51B | $24.54B | $19.61B | $18.67B | $17.87B | $14.98B | $11.76B | $11.66B | $11.03B | $10.46B | $10.15B | $11.39B | $20.5B | $17.56B | $16.92B | $14.49B | |
| — | 56.42% | 55.41% | 55.18% | 56.15% | 56.97% | 56.65% | 58.53% | 58.45% | 54.7% | 56.39% | 57.13% | 54.47% | 53.23% | 53.29% | 53.21% | 58.3% | 57.06% | 57.29% | 55.92% | |
| $2.99B | $2.94B | $2.84B | $2.74B | $2.89B | $2.74B | $2.42B | $2.44B | $2.3B | $2.26B | $1.45B | $1.41B | $1.35B | $1.37B | $1.46B | $1.51B | $3.72B | $2.74B | $2.69B | $2.51B | |
| $13.01B | $12.33B | $11.7B | $10.95B | $11.25B | $11.32B | $9.7B | $9.77B | $9.74B | $9.18B | $6.74B | $6.79B | $6.53B | $6.37B | $6.74B | $7.37B | $10.38B | $8.41B | $8.44B | $7.41B | |
| $1.68B | $1.68B | $1.88B | $1.97B | $2.01B | $2.05B | $2.13B | $1.94B | $2.18B | $1.98B | $550M | $601M | $630M | $791M | $1.42B | $1.65B | $1.42B | $878.53M | $787.1M | $782.03M | |
| — | — | — | — | — | — | $36M | $66M | $28M | — | — | — | — | — | $395M | $25M | $13M | $47M | — | — | |
| $37.43B | $36.28B | $35.13B | $33.63B | $35.29B | $34.65B | $29.25B | $27.37B | $26.93B | $25.83B | $17.83B | $17.54B | $17.65B | $17.52B | $17.69B | $19.78B | $29.08B | $24.53B | $23.83B | $21.34B | |
| $7.71B | $8.05B | $6.83B | $6.48B | $8.36B | $8.43B | $5.36B | $4.53B | $3.65B | $1.56B | $3.03B | $2.87B | $2.6B | $2.13B | $1.36B | $1.63B | $6.09B | $6.24B | $5.69B | $4.58B | |
| — | 18.17% | 16.27% | 16.15% | 19.16% | 19.56% | 15.48% | 14.21% | 11.94% | 5.71% | 14.51% | 14.05% | 12.84% | 10.85% | 7.14% | 7.61% | 17.31% | 20.27% | 19.28% | 17.67% | |
| $536M | $493M | $559M | $637M | $558M | $533M | $546M | $670M | $826M | $904M | $431M | $163M | $150M | $145M | $320M | $359M | $553.14M | $519.66M | $528.47M | $593.14M | |
| $332M | $308M | $344M | $385M | $183M | $43M | $46M | $94M | $105M | $124M | $99M | $105M | $77M | $67M | $59M | $65M | $105.45M | $137.78M | $201.23M | $136.75M | |
| $580M | $548M | $376M | $479M | $321M | $277M | $103M | $191M | $139M | $1.41B | -$786M | $281M | -$14M | $32M | $1M | -$119M | $62.01M | $1.38B | $454.94M | -$135.53M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $119M | $498.02M | |
| $8.14B | $8.47B | $7.01B | $6.66B | $8.31B | $8.21B | $4.97B | $4.08B | $2.87B | $2.23B | $1.41B | $3.18B | $2.52B | $2.04B | -$220M | $1.24B | $5.71B | $7.19B | — | — | |
| $1.86B | $1.94B | -$6.39B | $941M | $1.37B | $1.14B | $497M | $390M | $539M | $1.88B | $350M | $577M | $797M | $53M | -$457M | $110M | $1.09B | $1.45B | $1.12B | $863.33M | |
| $6.28B | $6.52B | $13.4B | $5.72B | $6.93B | $7.07B | $4.5B | $3.69B | $2.37B | $477M | $1.4B | $4.42B | $2.28B | $2.58B | $5.96B | $4.73B | $4.63B | $5.75B | $4.88B | $3.61B | |
| — | 14.72% | 31.95% | 14.27% | 15.88% | 16.42% | 12.99% | 11.56% | 7.74% | 1.74% | 6.71% | 21.68% | 11.28% | 13.1% | 31.3% | 22.09% | 13.15% | 18.68% | 16.53% | 13.92% | |
| $6.3B | $6.5B | $13.4B | $5.7B | $6.91B | $7.04B | $4.47B | $3.67B | $2.35B | $468M | $1.39B | $4.4B | $2.27B | $2.56B | $5.92B | $4.71B | $4.63B | $5.75B | — | — | |
| $7.38B | $8.43B | $13.34B | $5.94B | $7.26B | $7.64B | $4.01B | $2.81B | $1.18B | $1.53B | $795M | $2.69B | -$757M | $3.15B | — | — | $2.41B | $7.76B | $1.64B | — | |
| USD/shares | — | $3.73 | $7.67 | $3.28 | $3.94 | $3.97 | $2.52 | $2.07 | $1.34 | $0.27 | $0.94 | $2.94 | $1.50 | $1.64 | $3.76 | $3.03 | $2.98 | $3.71 | $3.16 | $2.34 |
| USD/shares | — | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 | $2.50 | $2.06 | $1.33 | $0.27 | $0.94 | $2.92 | $1.49 | $1.62 | $3.72 | $3.01 | $2.96 | $3.69 | $3.12 | $2.31 |
| shares | — | 1.74B | 1.74B | 1.74B | 1.75B | 1.78B | 1.77B | 1.77B | 1.76B | 1.74B | 1.48B | 1.5B | 1.52B | 1.56B | 1.58B | 1.56B | 1.55B | 1.55B | 1.55B | 1.54B |
| shares | — | 1.75B | 1.75B | 1.75B | 1.76B | 1.79B | 1.79B | 1.78B | 1.77B | 1.75B | 1.48B | 1.51B | 1.53B | 1.57B | 1.59B | 1.57B | 1.56B | 1.56B | 1.56B | 1.56B |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $23.82B in buybacks, $47.22B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
Compare industry multiplesEV/Revenue
—
Medical Devices median 3.70×
EV/EBIT
—
Medical Devices median 21.60×
P/E (TTM)
26.85×
Medical Devices median 27.00×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|---|---|
| Medical Devices | $11,370,000,000 | $12,239,000,000 | $11,787,000,000 | $14,485,000,000 | $14,802,000,000 | $16,887,000,000 | $18,986,000,000 | $21,387,000,000 |
| Diagnostic Products | $7,495,000,000 | $7,713,000,000 | $10,805,000,000 | $15,526,000,000 | $16,469,000,000 | $9,988,000,000 | $9,341,000,000 | $8,937,000,000 |
| Nutritional Products | $7,229,000,000 | $7,409,000,000 | $7,647,000,000 | $8,294,000,000 | $7,459,000,000 | $8,154,000,000 | $8,413,000,000 | $8,451,000,000 |
| Established Pharmaceutical Products | $4,422,000,000 | $4,486,000,000 | $4,303,000,000 | $4,718,000,000 | $4,912,000,000 | $5,066,000,000 | $5,194,000,000 | $5,536,000,000 |
| All Other Segments | $62,000,000 | $57,000,000 | — | — | — | — | — | — |
By Geography (USD)
| Component | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|---|---|
| Non Us | $19,739,000,000 | $20,506,000,000 | $21,586,000,000 | — | $25,511,000,000 | $24,657,000,000 | $25,627,000,000 | $27,202,000,000 |
| United States | $10,839,000,000 | $11,398,000,000 | $13,022,000,000 | $16,642,000,000 | $18,142,000,000 | $15,452,000,000 | $16,323,000,000 | $17,126,000,000 |
| All Other Countries | — | — | $12,823,000,000 | $15,726,000,000 | $15,010,000,000 | $14,168,000,000 | $14,786,000,000 | $15,979,000,000 |
| Germany | $1,619,000,000 | $1,751,000,000 | $2,108,000,000 | $2,572,000,000 | $2,340,000,000 | $2,345,000,000 | $2,539,000,000 | $2,759,000,000 |
| China | $2,311,000,000 | $2,346,000,000 | $1,965,000,000 | $2,392,000,000 | $2,133,000,000 | $2,253,000,000 | $2,113,000,000 | $1,907,000,000 |
| Switzerland | $1,005,000,000 | $1,068,000,000 | $1,140,000,000 | — | $1,336,000,000 | $1,638,000,000 | $1,747,000,000 | $1,871,000,000 |
| India | $1,333,000,000 | $1,397,000,000 | $1,323,000,000 | $1,561,000,000 | $1,649,000,000 | $1,750,000,000 | $1,817,000,000 | $1,871,000,000 |
| Japan | $1,326,000,000 | $1,435,000,000 | $1,386,000,000 | $1,695,000,000 | $1,932,000,000 | $1,513,000,000 | $1,441,000,000 | $1,475,000,000 |
| United Kingdom | — | — | — | — | — | $991,000,000 | $1,185,000,000 | $1,340,000,000 |
| Other Countries | $11,215,000,000 | $11,936,000,000 | $12,823,000,000 | — | — | — | — | — |
| Canada | — | $573,000,000 | $841,000,000 | $1,385,000,000 | $1,280,000,000 | — | — | — |
| Netherlands | $930,000,000 | $975,000,000 | $1,084,000,000 | $1,174,000,000 | $1,111,000,000 | $1,074,000,000 | $1,124,000,000 | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|---|---|
| Medical Devices | $3,500,000,000 | $3,769,000,000 | $3,038,000,000 | $4,533,000,000 | $4,436,000,000 | $5,306,000,000 | $6,153,000,000 | $7,212,000,000 |
| Diagnostic Products | $1,868,000,000 | $1,912,000,000 | $3,725,000,000 | $6,237,000,000 | $6,640,000,000 | $2,433,000,000 | $2,073,000,000 | $1,740,000,000 |
| Nutritional Products | $1,652,000,000 | $1,705,000,000 | $1,751,000,000 | $1,763,000,000 | $706,000,000 | $1,333,000,000 | $1,505,000,000 | $1,558,000,000 |
| Established Pharmaceutical Products | $894,000,000 | $904,000,000 | $794,000,000 | $889,000,000 | $1,049,000,000 | $1,206,000,000 | $1,233,000,000 | $1,290,000,000 |
Operating Margin by Segment (%)
| Component | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|---|---|
| Medical Devices | 30.8% | 30.8% | 25.8% | 31.3% | 30% | 31.4% | 32.4% | 33.7% |
| Diagnostic Products | 24.9% | 24.8% | 34.5% | 40.2% | 40.3% | 24.4% | 22.2% | 19.5% |
| Nutritional Products | 22.9% | 23% | 22.9% | 21.3% | 9.5% | 16.3% | 17.9% | 18.4% |
| Established Pharmaceutical Products | 20.2% | 20.2% | 18.5% | 18.8% | 21.4% | 23.8% | 23.7% | 23.3% |